$201 Million is the total value of Knoll Capital Management, LLC's 40 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 9.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BHVN | Biohaven Pharmactl Hldg Co L | $119,024,000 | +43.1% | 856,844 | 0.0% | 59.36% | +36.6% | |
| APLT | Applied Therapeutics Inc | $17,133,000 | -20.1% | 1,032,123 | 0.0% | 8.54% | -23.7% | |
| ENTX | Entera Bio Ltd | $11,701,000 | -21.2% | 2,484,275 | 0.0% | 5.84% | -24.8% | |
| ORGS | Orgenesis, Inc. | $6,516,000 | -2.4% | 1,316,364 | 0.0% | 3.25% | -6.8% | |
| CRBP | Corbus Pharmaceuticals HLDGS | $5,147,000 | -44.3% | 5,045,870 | 0.0% | 2.57% | -46.8% | |
| ALDX | Aldeyra Therapeutics Inc | $4,999,000 | -22.5% | 569,405 | 0.0% | 2.49% | -26.0% | |
| EIGR | Eiger Biopharmaceuticals Inc | $4,637,000 | -21.6% | 694,232 | 0.0% | 2.31% | -25.2% | |
| Anavex Life Sciemves Corp | $3,784,000 | -21.5% | 210,789 | 0.0% | 1.89% | -25.0% | ||
| ABEO | Abeona Therapeutics Inc | $3,203,000 | -28.2% | 2,859,767 | 0.0% | 1.60% | -31.5% | |
| BX | Sell | Blackstone Group LP | $2,792,000 | -4.2% | 24,000 | -20.0% | 1.39% | -8.5% |
| ALT | Buy | Altimmune Inc | $1,504,000 | +35.1% | 132,978 | +166.0% | 0.75% | +29.1% |
| AMD | Advanced Micro Deviced Inc | $1,270,000 | +9.5% | 12,350 | 0.0% | 0.63% | +4.5% | |
| LUMN | Sell | Lumen Technologies Inc | $1,239,000 | -58.6% | 100,000 | -54.5% | 0.62% | -60.4% |
| CVS | CVS Health Corp | $1,230,000 | +1.7% | 14,500 | 0.0% | 0.61% | -3.0% | |
| TMO | Thermo Fischer Scientific Inc | $1,200,000 | +13.3% | 2,100 | 0.0% | 0.60% | +8.1% | |
| ANET | Arista Networks Inc | $1,186,000 | -5.1% | 3,450 | 0.0% | 0.59% | -9.5% | |
| V | Visa | $1,080,000 | -4.8% | 4,850 | 0.0% | 0.54% | -9.0% | |
| BAH | Booz Allen Hamilton HLDG CORcl a | $1,032,000 | -6.8% | 13,000 | 0.0% | 0.52% | -10.9% | |
| MO | Altria Group Inc | $1,033,000 | -4.5% | 22,700 | 0.0% | 0.52% | -8.8% | |
| VMW | VMWare Inc | $1,033,000 | -7.1% | 6,950 | 0.0% | 0.52% | -11.4% | |
| GLW | Corning Inc | $971,000 | -10.8% | 26,600 | 0.0% | 0.48% | -14.8% | |
| XCUR | Sell | Exicure | $962,000 | -49.8% | 801,922 | -37.2% | 0.48% | -52.0% |
| ASML | New | ASML Holdings | $912,000 | – | 1,280 | +100.0% | 0.46% | – |
| SNGX | Soligenix Inc. | $835,000 | -4.5% | 787,830 | 0.0% | 0.42% | -8.8% | |
| BTAI | BioXCel Therapeutics Inc | $607,000 | +4.5% | 20,000 | 0.0% | 0.30% | 0.0% | |
| ANGN | Angion BioMedica Corp | $586,000 | -25.0% | 60,000 | 0.0% | 0.29% | -28.4% | |
| MMX | MAVERIX METALS INC | $514,000 | -17.1% | 115,000 | 0.0% | 0.26% | -21.0% | |
| SA | SEABRIDGE GOLD INC | $494,000 | -12.1% | 32,000 | 0.0% | 0.25% | -16.0% | |
| FNV | FRANCO NEV CORP | $487,000 | -10.5% | 3,750 | 0.0% | 0.24% | -14.4% | |
| ANVS | Sell | Annovis | $451,000 | -86.6% | 14,210 | -63.8% | 0.22% | -87.2% |
| KL | KIRKLAND LAKE GOLD LTD | $447,000 | +8.0% | 10,750 | 0.0% | 0.22% | +3.2% | |
| AEM | AGNICO EAGLE MINES LTD | $358,000 | -14.1% | 6,900 | 0.0% | 0.18% | -17.9% | |
| OR | OSISKO GOLD ROYALTIES LTD | $357,000 | -24.7% | 190,000 | 0.0% | 0.18% | -28.2% | |
| AGTC | Applied genetiv therapies | $301,000 | -23.0% | 100,000 | 0.0% | 0.15% | -26.5% | |
| EQX | EQUINOX GOLD CORP | $300,000 | -5.1% | 45,500 | 0.0% | 0.15% | -9.1% | |
| SILV | SILVERCREST METALS INC | $293,000 | -20.2% | 42,000 | 0.0% | 0.15% | -24.0% | |
| MAG | MAG SILVER CORP | $280,000 | -22.7% | 17,300 | 0.0% | 0.14% | -25.9% | |
| SVM | SILVERCORP METALS INC | $267,000 | -30.5% | 70,000 | 0.0% | 0.13% | -33.8% | |
| PAAS | PAN AMERN SILVER CORP | $191,000 | -18.4% | 8,200 | 0.0% | 0.10% | -22.1% | |
| FSM | FORTUNA SILVER MINES INC | $172,000 | -32.0% | 43,700 | 0.0% | 0.09% | -34.8% | |
| DD | Exit | Dupont de Nemours Inc | $0 | – | -15,000 | -100.0% | -0.61% | – |
| CTVA | Exit | Corteva Inc | $0 | – | -30,000 | -100.0% | -0.70% | – |
| DOW | Exit | Dow Inc | $0 | – | -30,000 | -100.0% | -0.99% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Aldeyra Therapeutics Inc | 35 | Q3 2023 | 31.6% |
| Corbus Pharmaceuticals HLDGS | 30 | Q3 2022 | 46.5% |
| Abeona Therapeutics Inc | 30 | Q3 2022 | 34.8% |
| Biohaven Pharmactl Hldg Co L | 26 | Q3 2023 | 79.6% |
| Entera Bio Ltd | 22 | Q3 2023 | 7.8% |
| Ampio Pharmaceuticals Inc. | 21 | Q2 2018 | 11.0% |
| Soligenix Inc. | 20 | Q3 2022 | 1.7% |
| Eiger Biopharmaceuticals Inc | 19 | Q3 2022 | 5.8% |
| Applied Therapeutics Inc | 18 | Q3 2023 | 19.7% |
| Alcobra Ltd | 18 | Q3 2017 | 6.5% |
View Knoll Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| HOOKIPA Pharma Inc. | June 20, 2023 | 5,517,385 | 6.8% |
| Applied Therapeutics Inc. | January 23, 2023 | 3,450,000 | 7.2% |
| Orgenesis Inc. | August 14, 2020 | 1,316,364 | 5.9% |
| Corbus Pharmaceuticals Holdings, Inc. | February 14, 2020 | 5,045,870 | 7.1% |
| ABEONA THERAPEUTICS INC. | February 14, 2018 | 2,359,767 | 5.0% |
| SOLIGENIX, INC. | November 13, 2017 | 870,000 | 9.9% |
| ABEONA THERAPEUTICS INC. | February 14, 2017 | 2,359,767 | 5.9% |
| ALCOBRA LTD. | February 14, 2017 | 1,205,498 | 4.4% |
| Ampio Pharmaceuticals, Inc. | February 14, 2017 | 2,738,322 | 4.8% |
| RITTER PHARMACEUTICALS INC | February 14, 2017 | 952,434 | 8.2% |
View Knoll Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-01-16 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-04 |
| 13F-HR | 2023-08-15 |
| SC 13G | 2023-06-20 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-01-23 |
| 13F-HR | 2022-11-14 |
View Knoll Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.